Effect of intravenous immunoglobulin therapy on plasma complement

Transfusion Science

Volumn 19, Issue 4, 1998, Pages 307-318

  Wegmüller, Edgar ^a  

^a Regionalspital Interlaken ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOLYSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOGAMMAGLOBULINEMIA; IMMUNE COMPLEX DISEASE; INTRAVENOUS DRUG ADMINISTRATION; MALE; SCHOOL CHILD;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; ANTIGEN-ANTIBODY COMPLEX; COMMON VARIABLE IMMUNODEFICIENCY; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C3B; COMPLEMENT SYSTEM PROTEINS; FEMALE; GAMMA-GLOBULINS; HEMOLYSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; X CHROMOSOME;

EID: 0032436989     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(98)00055-1     Document Type: Article

References (22)

1. Wien MW, Filman DJ, Stura EA, Guillot S, Delpeyroux F, Crainic R, Hogle JM: Structure of the complex between the Fab fragment of a neutralizing antibody for type 1 poliovirus and its viral epitope. Nature Structural Biol. 1995; 2:232-243.
2. Kraus D, Medof ME, Mold C: Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H. Infect. Immun. 1998; 66:399-405.
3. Brekke OH, Michaelsen TE, Sandlie I: The structural requirements for complement activation by IgG: Does it hinge on the hinge? Immunol. Today 1995; 16:85-89.
4. Sahu A, Pangburn MK: Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linage formation. J. Biol. Chem. 1994; 269:28997-29000.
5. Nydegger UE, Hauser SP: Use of intravenous immunoglobulins in haematological disorders. Clinical Immunotherapy 1996; 5:465-485.
6. Stangel M, Gold R: Treatment with intravenous immunoglobulins in critical care of neuromuscular disorders. Infusionsther Transfusionsmed 1997; 24:171-177.
7. Fazekas F, Deisenhammer F, Strasser-Fuchst S, Nahler G, Mamooi B: Randomised pacebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349:589-593.
8. Leung DYM, Burns J, Newburger J, Geha RS: Reversal of immunoregulatory abnormalities in Kawasaki syndrome by intravenous gammaglobulin. J. Clin. Invest. 1987; 79:468-472.
9. Werdan K, Pilz G: Supplemental immune globulins in sepsis: A critical appraisal. Clin. Exp. Immunol. 1996; 104:83-88.
10. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 1994; 94:1729-1735.
11. Mollnes TE, Hogasen BF, Hoaas BF, Michaelsen TE, Garred P, Harboe M: Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the Ig isotype and its C1 binding properties. Scand. J. Immunol. 1995; 41:449-456.
12. Lutz HU, Stammler O, Jelezarova E, Nater M, Spaeth PJ: High doses of immunoglobulin G attenuated immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3b(n)-IgG complexes. Blood 1996; 88:184-193.
13. Miletic VD, Hester CG, Frank MM: Regulation of complement activity by immunoglobulin 1. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J. Immunol. 1996; 156:749-757.
14. Nydegger UE: Safety and side effects of i.v. immunoglobulin therapy. Clin. Exp. Rheumatol. 1996; 14(suppl 15):S53-S57.
15. Nydegger UE, Ackermann LM, Lambert PH, Miescher PA: A simple automated method for complement estimation in a continuous flow System. J. Immunol. 1972; 109:910-913.
16. Perrin LM, Lambert PH, Miescher PA: Complement breakdown products in plasma from patients with membrano-proliferative or other glomerulonephritis. J. Clin. Invest. 1975; 56:165-176.
17. Zubler RH, Lange G, Lambert PH: Detection of immune complexes in unheated sera by a modified 125 I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus. J. Immunol. 1976; 116:232-235.
18. Kazatchkine MD, Kaveri SS, Nydeggar UE, Sultan Y: Variable (V) region-mediated control of autoreactivity to factor VII. Adv. Exp. Med. Biol. 1995; 386:223-228.
19. Kohler PF, Müller-Eberhard HJ: Complement immunoglobulin deficiency of Clq associated with impaired immunoglobulin G synthesis. Science 1968; 163:474-475.
20. Kohler PF, Müller-Eberhard HJ: Metabolism of human Clq. Studies in hypogammaglobulinaemia, myeloma and systemic lupus erythematosus. J. Clin. Invest. 1972; 51:868-875.
21. Cunningham-Rundles C: Normalization of serum Clq after intravenous immunoglobulin infusions in hypogammaglobulinemia: Dependence upon methods of immunoglobulin preparation. Clin. Immunol. Immunopathol. 1984; 33:176-181.
22. Basta M, Kirshbom P, Frank MM, Fries LF: Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J. Clin. Invest. 1989; 84:1974-1981.